DHR vs MRK
Danaher · Merck
| DHR Danaher Healthcare | MRK Merck Healthcare | |
|---|---|---|
| Market | ||
| Price | $232.23 -2.00% | $149.52 +2.18% |
| Market cap | $163.4B | $368.9B |
| P/E (TTM) | 37.7 | 116.3 |
| Dividend yield | 0.49% | 2.87% |
| 52-week range | $160.93 – $242.80 | $82.01 – $156.92 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Danaher (DHR): Core Sales Up 3% And Adjusted EPS Up 11.5%, But A Tax Swing Was 81% Of The… Nov 1, 2026 | Merck (MRK): Revenue Up 5%, But $550M Of Purchase Timing Was About Two-Thirds Of The Incr… Nov 1, 2026 |
| Latest earnings | ||
| Reported | Oct 21, 2026 | Oct 29, 2026 |
| Revenue | $6.6 billion +8.5% YoY | — |
| EPS | — | $2.04 |
| Guidance | Guidance revised | Guidance issued |
| Revenue growth, last 4 reports | +8.5% | — |
| Topics | ||
| Main topics | ||
| Company page · Earnings releases | Company page · Earnings releases | |
Shared topics: Earnings Quality Guidance Margins
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.